Compare Stocks: IRON, MDGL, HALO, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HALO Halozyme Therapeutics	$98.66 -2.0%	$79.66	$61.22 ▼ $104.78	$11.43B	0.85	2.33 million shs	1.66 million shs
IRON Disc Medicine	$78.84 -1.5%	$74.60	$40.00 ▼ $99.50	$306.80M	1	326,915 shs	262,542 shs
MDGL Madrigal Pharmaceuticals	$507.56 +0.0%	$519.31	$351.32 ▼ $615.00	$11.72B	-1.01	394,147 shs	234,655 shs
SMMT Summit Therapeutics	$13.35 -4.6%	$14.23	$12.25 ▼ $30.05	$11.17B	-1.23	4.00 million shs	9.74 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HALO Halozyme Therapeutics	-2.00%	-4.33%	+30.12%	+46.99%	+51.48%
IRON Disc Medicine	-1.46%	+1.81%	+3.71%	+17.92%	+29.03%
MDGL Madrigal Pharmaceuticals	+0.04%	-0.49%	-7.76%	-3.08%	+35.91%
SMMT Summit Therapeutics	-4.64%	-4.37%	-11.41%	-20.87%	-50.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HALO Halozyme Therapeutics	$98.66 -2.0%	$79.66	$61.22 ▼ $104.78	$11.43B	0.85	2.33 million shs	1.66 million shs
IRON Disc Medicine	$78.84 -1.5%	$74.60	$40.00 ▼ $99.50	$306.80M	1	326,915 shs	262,542 shs
MDGL Madrigal Pharmaceuticals	$507.56 +0.0%	$519.31	$351.32 ▼ $615.00	$11.72B	-1.01	394,147 shs	234,655 shs
SMMT Summit Therapeutics	$13.35 -4.6%	$14.23	$12.25 ▼ $30.05	$11.17B	-1.23	4.00 million shs	9.74 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HALO Halozyme Therapeutics	-2.00%	-4.33%	+30.12%	+46.99%	+51.48%
IRON Disc Medicine	-1.46%	+1.81%	+3.71%	+17.92%	+29.03%
MDGL Madrigal Pharmaceuticals	+0.04%	-0.49%	-7.76%	-3.08%	+35.91%
SMMT Summit Therapeutics	-4.64%	-4.37%	-11.41%	-20.87%	-50.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-7.56% Downside
IRON Disc Medicine	2.75	Moderate Buy	$106.00	34.45% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$689.93	35.93% Upside
SMMT Summit Therapeutics	2.38	Hold	$24.25	81.61% Upside

Current Analyst Ratings Breakdown

Latest IRON, MDGL, HALO, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$12.00 ➝ $13.00
8/7/2026	HALO Halozyme Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $105.00
8/7/2026	HALO Halozyme Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$92.00 ➝ $93.00
8/7/2026	HALO Halozyme Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$75.00 ➝ $95.00
8/7/2026	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$83.00 ➝ $110.00
8/7/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $115.00
8/6/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/6/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$118.00 ➝ $120.00
8/4/2026	MDGL Madrigal Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$605.00
8/3/2026	MDGL Madrigal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$964.00 ➝ $962.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HALO Halozyme Therapeutics	$1.40B	8.02	$4.68 per share	21.10	$1.26 per share	78.30
IRON Disc Medicine	N/A	N/A	N/A	N/A	$167.99 per share	N/A
MDGL Madrigal Pharmaceuticals	$958.40M	12.23	N/A	N/A	$22.67 per share	22.39
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HALO Halozyme Therapeutics	$316.89M	$3.35	29.45	10.65	0.40	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	N/A
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	91.45	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest IRON, MDGL, HALO, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HALO Halozyme Therapeutics	13.50	2.71	2.31
IRON Disc Medicine	0.09	24.14	24.14
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HALO Halozyme Therapeutics	97.79%
IRON Disc Medicine	83.70%
MDGL Madrigal Pharmaceuticals	98.50%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
HALO Halozyme Therapeutics	2.50%
IRON Disc Medicine	3.76%
MDGL Madrigal Pharmaceuticals	17.60%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable
IRON Disc Medicine	30	3.83 million	3.69 million	Not Optionable
MDGL Madrigal Pharmaceuticals	90	23.10 million	19.04 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

IRON, MDGL, HALO, and SMMT Headlines

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Here's Why

August 14 at 11:59 AM | marketbeat.com

Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT

August 14 at 3:43 AM | marketbeat.com

Leerink Partners Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Market Perform"

August 14 at 1:54 AM | americanbankingnews.com

Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum?

August 13 at 1:03 AM | kalkinemedia.comK

Summit Therapeutics Inc Share Chat (SMMT.US)

August 12 at 8:02 PM | lse.co.uk

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

August 12 at 9:22 AM | businesswire.com

Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners

August 12 at 9:05 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Cross Above 50 Day Moving Average - What's Next?

August 12 at 3:40 AM | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?

August 12 at 3:39 AM | marketbeat.com

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

August 7, 2026 | barrons.com

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

August 5, 2026 | finance.yahoo.com

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

August 4, 2026 | benzinga.com

The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT

August 4, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts

August 3, 2026 | marketbeat.com

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

July 31, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

July 30, 2026 | theglobeandmail.com

What is HC Wainwright's Estimate for SMMT FY2026 Earnings?

July 29, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

July 29, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Hits New 12-Month Low - Time to Sell?

July 28, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

July 27, 2026 | prnewswire.com

SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

July 24, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRON, MDGL, HALO, and SMMT Company Descriptions

Halozyme Therapeutics NASDAQ:HALO

$98.66 -2.01 (-2.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$98.08 -0.58 (-0.59%)

As of 08/14/2026 07:34 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Disc Medicine NASDAQ:IRON

$78.84 -1.17 (-1.46%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$79.00 +0.16 (+0.20%)

As of 08/14/2026 07:34 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Madrigal Pharmaceuticals NASDAQ:MDGL

$507.56 +0.19 (+0.04%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$505.02 -2.55 (-0.50%)

As of 08/14/2026 07:34 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Summit Therapeutics NASDAQ:SMMT

$13.35 -0.65 (-4.64%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$13.39 +0.04 (+0.30%)

As of 08/14/2026 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRON, MDGL, HALO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRON, MDGL, HALO, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRON, MDGL, HALO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRON, MDGL, HALO, and SMMT Company Descriptions

Halozyme Therapeutics NASDAQ:HALO

Disc Medicine NASDAQ:IRON

Madrigal Pharmaceuticals NASDAQ:MDGL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRON, MDGL, HALO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRON, MDGL, HALO, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRON, MDGL, HALO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRON, MDGL, HALO, and SMMT Company Descriptions

Halozyme Therapeutics NASDAQ:HALO

Disc Medicine NASDAQ:IRON

Madrigal Pharmaceuticals NASDAQ:MDGL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools